erlotinib hydrochloride has been researched along with Alport Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, R; Kai, H; Kai, Y; Kamura, M; Miyakita, R; Omachi, K; Shuto, T; Suico, MA; Yokota, T | 1 |
1 other study(ies) available for erlotinib hydrochloride and Alport Syndrome
| Article | Year |
|---|---|
Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.
Topics: Animals; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Female; Kidney; Male; Mice; Nephritis, Hereditary | 2017 |